ALX ONCOLOGY HOLDINGS INC Payments to Acquire in Process Research and Development
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Payments to Acquire in Process Research and Development of $4.26 million for the 12-month period ending 2021-12-31, per its 10-K filed 2024-03-07.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment · last filed 2024-03-07
- ALX ONCOLOGY HOLDINGS INC payments to acquire in process research and development for fiscal 2021 was $4.26M.
| Period end | Payments to Acquire in Process Research and Development 12 month |
|---|---|
| 2021-12-31 | $4.26M 10-K · filed 2024-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |